The development of vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors for the treatment of renal cancer is a real success story.
Walter M. Stadler, MD, FACP
Advertisement
Articles by Walter M. Stadler, MD, FACP
Advertisement
Latest Updated Articles
- Renal Cancer Therapeutics: Now What?
Published: March 13th 2012 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Sevabertinib in Non-Squamous NSCLC
2
Tarlatamab Earns Traditional FDA Approval in ES-SCLC
3
FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas
4
FDA Traditionally Approves Daratumumab Regimen in AL Amyloidosis
5
